Article

Sightpath Medical: New name for MSS and LaserVision

Minneapolis-Sightpath Medical is the new name encompassing MSS and LaserVision-a mobile access cataract and glaucoma surgical services provider and product distributor, and a mobile access refractive surgical services business, respectively.

Minneapolis-Sightpath Medical is the new name encompassing MSS and LaserVision-a mobile-access cataract and glaucoma surgical services provider and product distributor, and a mobile-access refractive surgical services business, respectively. Operating as divisions of Sightpath Medical, a wholly owned subsidiary of TLC Vision Corp., both companies’ products and services will be combined under the new name.

“Our new name helps emphasize our dedication to helping clients create the ‘best path to sight’ for their patients,” said Jim Tiffany, president of Sightpath Medical. “By providing our doctors and eye-care facility partners with leading ophthalmic technologies and innovative, customized solutions, we create paths for them to develop the service offerings they want.”

MSS was founded in Minneapolis in 1991 and offers cataract and glaucoma services throughout 41 states, serving more than 500 customers.

LaserVision was founded in St. Louis and moved to Minneapolis in 2007. It currently markets to more than 600 customers who offer refractive services in 48 states. It provides access to transportable and fixed-based excimer lasers, femtosecond lasers, wavefront analyzers, and related surgical equipment and personnel.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.